23 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 23 of 23 clinical reviews.
MD-level guide to every clinically significant ezetimibe drug-drug interaction, including statins, fibrates, cyclosporine, bile acid sequestrants, and anticoagulants, with PubMed-cited evidence.
Evidence-based guide to ezetimibe (Zetia) 10 mg dosing in adults aged 50-64, covering IMPROVE-IT trial data, polypharmacy considerations, statin combination therapy, and monitoring protocols.
Clinical guide to ezetimibe (Zetia) dosing in patients with renal impairment, including pharmacokinetic data, FDA labeling, guideline recommendations, and monitoring considerations.
Evidence-based guide to ezetimibe (Zetia) storage conditions, chemical stability, shelf life, and what to do if tablets are exposed to heat, light, or humidity.
Ezetimibe is usually taken as 10 mg once daily. Learn which medicines change its timing, what LDL trials show, and how heart-event evidence differs.
Ezetimibe meal timing, the two bile-acid-sequestrant options, and evidence on sterols, CoQ10 and common supplements, with a schedule worksheet.
Yes, ezetimibe has a favorable safety profile since 2002, with rare liver and muscle risks monitored by the FDA. No black box warnings or withdrawals.
Planning to stop ezetimibe? Record the exact ingredient change, compare dated LDL results, and separate treatment response from cardiovascular benefit.
Evidence-based protocols for switching between ezetimibe (Zetia) and other lipid-lowering drugs, including statins, PCSK9 inhibitors, and bempedoic acid. Covers timing, dose adjustments, and monitoring.
Compare the cost of generic ezetimibe to statins, PCSK9 inhibitors, bempedoic acid, and inclisiran. Includes trial evidence, mechanism of action, and practical prescribing guidance.
A clinical deep-dive into ezetimibe's manufacturing timeline, FDA supply chain events, generic entry, and shortage history from 2002 to present.
Evidence-based missed-dose protocol for ezetimibe (Zetia). Learn when to take a late dose, when to skip, and how missed doses affect your cholesterol control.
A week-by-week breakdown of what happens in your first month on ezetimibe (Zetia), including LDL changes, side effects, timelines, and IMPROVE-IT trial data prepared by the HealthRX.com Editorial Team.
Does ezetimibe (Zetia) change appetite or food cravings? A deep dive into the pharmacology, clinical trial data, and patient reports that answer this question.
A guide to ezetimibe (Zetia) use in autoimmune disease, covering drug interactions, immune effects, cardiovascular benefit in lupus and RA, safety data from IMPROVE-IT, and practical dosing guidance.
A deep clinical review of ezetimibe's long-term cardiovascular impact, grounded in IMPROVE-IT, SHARP, and current ACC/AHA guidelines. Learn what the trial data show, who benefits most, and how to use ezetimibe in practice.
A clinician-level review of ezetimibe (Zetia) and cognition, covering IMPROVE-IT data, FDA post-market surveillance, proposed mechanisms, and how to counsel patients asking about memory or cognitive side effects.
A clinical deep-dive into ezetimibe (Zetia) and its documented effects on hair and skin, including alopecia, rash, and urticaria reports from postmarketing data, IMPROVE-IT trial findings, and FDA labeling.
Ezetimibe alone raises ALT or AST above 3x ULN in about 0.4% of patients, rising to 1.3% with a statin. These elevations are reversible and usually silent.
A physician-level explanation of how ezetimibe (Zetia) blocks intestinal cholesterol absorption through NPC1L1, lowers LDL-C, and complements statin therapy.
A deep dive into ezetimibe (Zetia) and its effects on mental health, mood, depression, and cognitive function. Covers IMPROVE-IT data, pharmacology, and clinical guidance.
Evidence-based ezetimibe (Zetia) monitoring schedule covering lipid panels, liver function tests, CK levels, and follow-up exam timing. MD-level depth with PubMed and FDA citations.
A comprehensive MD/PharmD-level guide to ezetimibe (Zetia) pre-operative management, hold timing, cardiovascular risk bridging, and resumption protocols, with primary-literature citations throughout.